Form 4: Emergent BioSolutions Executive Discloses Routine Stock Disposition for Tax Purposes

Emergent BioSolutions Inc. EVP Coleen Glessner reported a routine disposition of 1,249 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Coleen Glessner, Executive Vice President, Quality & Ethics, and Chief Public Liaison (CPL) of Emergent BioSolutions Inc. (EBS), reported a transaction on June 8, 2025.
• The transaction involved the disposition of 1,249 shares of Emergent BioSolutions common stock.
• These shares were withheld by the issuer to pay taxes associated with the vesting and settlement of restricted stock units.
• The price per share for the disposition was $6.63.
• Following this transaction, Ms. Glessner beneficially owns 174,927 shares of Emergent BioSolutions common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine administrative transaction (shares withheld for taxes) and does not indicate any operational or financial performance changes for the company, thus having a neutral sentiment.

Positives

• The transaction indicates the vesting of restricted stock units, which is a common form of executive compensation designed to align management interests with shareholder value.

Negatives

• The disposition of shares, while for tax purposes, results in a slight reduction in the insider's direct beneficial ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Minimal impact on shareholders as this is a routine administrative transaction related to executive compensation and tax obligations.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Emergent BioSolutions, EBS, Form 4, Insider Transaction, Stock Disposition, Restricted Stock Units, Tax Withholding, Coleen Glessner, SEC Filing